How Long Do Retatrutide Side Effects Last? What the Trials Show

How long do retatrutide side effects last? It depends on which one you mean. In Lilly's trials, stomach side effects bunched up in the weeks when the dose was rising and then subsided over time, while the rise in heart rate peaked at week 24 in Phase 2, long after the last dose step. No trial has published a day count for any symptom, so nobody can honestly promise you "three days" or "two weeks". The pattern is consistent, though: expect symptoms after each dose increase, and expect them to ease if you hold a dose.

The trials show when symptoms cluster. They can't say how many days yours will run.

When do retatrutide side effects start?

Most stomach side effects show up while the dose climbs. Lilly reported that in its Phase 2 obesity trial they usually came during the dose escalation period. In the Phase 3 TRANSCEND-T2D-1 trial, nausea, diarrhea and vomiting also happened mainly during escalation.

Escalation begins with your very first shot. In the Phase 3 trials Lilly has reported, people started at 2 mg once a week and stepped up every 4 weeks (2, 4, 6, 9, then 12 mg), so reaching 12 mg took 16 weeks. In the Phase 2 obesity trial, all dose steps were finished by week 12. The starting dose guide covers that first 2 mg month.

Within a single week, timing follows the blood level. Lilly Medical Information says retatrutide reaches its highest concentration within 12 to 72 hours of a dose, and its half-life is about 6 days. Our read: if a symptom tracks the blood level, the first one to three days after the shot are when to expect it, easing as the week goes on. No trial has matched symptoms to days after the shot, so that's an inference, not a finding.

The tirzepatide label points the same way: that drug's delay in stomach emptying is largest after the first dose and diminishes over time. That's class evidence, not retatrutide data. Use our retatrutide dosing schedule to see where each step falls.

How long do retatrutide side effects last, window by window

Think in windows rather than one countdown.

Each step is also a new blood level to settle into. By our arithmetic from the 6-day half-life, four weekly shots at a new dose reach about 96% of that dose's steady-state level, which fits the 4-week spacing of the Phase 3 steps. Lilly hasn't said that's the reason; our half-life guide shows the math.

How long each common side effect usually lasts

Each symptom follows its own pattern, with its own gaps. The table pairs how common each one was with what the data say about timing.

Nausea, diarrhea and vomiting

These are the classic dose-step symptoms. The 2026 Lancet report of TRANSCEND-T2D-1 described them as mostly mild to moderate and said they subsided over time, and a Nature Medicine analysis of Phase 2 participants with fatty liver called them transient. In the newest trial, TRANSCEND-T2D-2 (reported Oct 28, 2026), nausea was 21.2% on 9 mg and 23.8% on 12 mg against 21.3% on Ozempic 2 mg, so nausea ran at about the Ozempic rate. Lilly's release doesn't say how long they lasted. For ways to take the edge off while they settle, see our guide to retatrutide nausea.

Constipation is less clear. Lilly listed it among the most common side effects but didn't describe its timing, so the data can't tell you whether it fades on the same schedule.

Heart rate

Heart rate follows a slower clock. In the Phase 2 obesity trial, the rise in heart rate grew with dose, peaked at week 24 and then declined, even though the last dose step came at week 12. The abstract doesn't give the size of the rise; for comparison only, the tirzepatide label reports an average increase of 1 to 3 beats per minute. If your heart races or pounds while you're at rest, tell your doctor, as the Wegovy label asks patients to do.

Skin sensitivity

Skin sensitivity (dysesthesia) means skin that feels sore, burning or oversensitive to touch. Across the six Phase 3 trials it affected 2.3% to 20.9% of people on retatrutide, versus 0% to 1.3% on placebo and 2.7% on Ozempic in TRANSCEND-T2D-2, with the highest rate on 12 mg in TRIUMPH-4. Lilly reported that most cases were mild to moderate and that the majority resolved while people stayed on treatment. How long a typical episode lasts hasn't been published.

The best clue comes from semaglutide 7.2 mg, a related drug. Its label says 18% of people with dysesthesia didn't report recovering during the trial, and that events resolved faster when the dose was lowered, paused or stopped. That's class evidence.

Fatigue, sleep, injection sites and mood

Fatigue showed up in 9.7% of the 12 mg group in the Phase 2 obesity trial versus 4.3% on placebo, with no timing data. Sleep problems and injection site reactions didn't reach the 5% reporting threshold in any group of either Phase 2 trial. Our guides cover insomnia, injection site reactions, hair loss and mood changes separately.

Why side effects come back after a dose increase

A new dose step can restart the adjustment. The trials concentrated stomach side effects in the escalation weeks, and Phase 2 showed that the size of the jump matters. People who started at 4 mg instead of 2 mg had far more nausea on the same target dose.

Nausea on placebo was 11.4% in the obesity trial and 4.4% in the diabetes trial. In the diabetes trial, mild to moderate stomach side effects overall peaked at 50% (12 of 24) in the 8 mg group that started at 4 mg. Phase 3 then started everyone at 2 mg with 4-week steps.

One possible reason is adaptation: if the gut settles into a dose, a bigger one asks it to adjust again. Nobody has measured that for retatrutide.

Skin sensitivity can come back too, at least with a related drug. On semaglutide 7.2 mg, 17 of 38 people (45%) who were stepped back up after their dysesthesia resolved had it come back, according to the Wegovy label. Treat that as a warning sign for retatrutide rather than a forecast.

Do retatrutide side effects go away?

In the trials, mostly yes, and most people stayed on. The 2026 Lancet paper on TRANSCEND-T2D-1 reported that the stomach side effects subsided over time, and only 2.2% to 5.1% of people on retatrutide stopped because of side effects, against 0.0% on placebo. Stopping was more common in the obesity trials and rose with dose in most of them.

Our read: the rate climbs with dose in most of these trials (TRIUMPH-2 is the exception, with 9 mg above 12 mg), which fits a dose-related effect. The trials can't separate the dose itself from the steps needed to reach it. In TRIUMPH-1, the 4 mg group stopped less often than placebo did.

In TRIUMPH-4, Lilly said the 18.2% on 12 mg tracked with starting BMI and included people who felt they were losing too much weight; it was 12.1% at a BMI of 35 or more. What the trials don't show is how many people had a symptom that never fully cleared. Stopping rates count only the people who quit, not the people who pushed through symptoms that lingered.

What if your side effects don't fade?

A symptom that stops improving is worth a call to your doctor. Even inside Lilly's trials, stepping down was allowed: the TRIUMPH-1 extension only enrolled people who finished without a permanent dose reduction, which tells you such reductions were part of the protocol.

Labels for approved drugs in the same class build that in. The Wegovy label says to consider delaying the next step by 4 weeks if a dose isn't tolerated, and the Zepbound label says to consider a lower maintenance dosage. So if a symptom isn't easing at a steady dose, ask your doctor about holding it longer or stepping back to the last dose you tolerated. Make that call with them.

Check the product as well. No approved retatrutide exists yet. Lilly last said, on September 29, 2026, that it plans to submit retatrutide to the FDA in the first quarter of 2027 as a Biologics License Application (BLA). On October 2, 2026, the FDA decided that retatrutide is a drug, not a biological product, so an application would need to be filed under section 505 of the Federal Food, Drug, and Cosmetic Act. Lilly's appeal on that question is pending in the Seventh Circuit, and we found no ruling as of October 31, 2026.

Lilly also warns that products sold outside its trials may contain too much or too little active ingredient, and a vial stronger than its label can act like a dose step you never planned. One BMJ Case Reports paper (October 2026) described a woman in her mid-20s with 5 days of refractory nausea and vomiting after 4 weekly, escalating injections of an unverified product reported to contain retatrutide; it resolved within a week. That's one case, not a trial. If you're comparing retatrutide for sale, favor sellers that publish batch-specific third-party tests for identity and content, and read is retatrutide safe first.

How long do side effects last after stopping?

Stopping doesn't switch retatrutide off overnight. With a half-life of about 6 days, blood levels fall by roughly half each week after your last shot, so the drug takes several weeks to clear. No retatrutide trial has published how quickly side effects fade after stopping.

Levels fall gradually rather than all at once, so a symptom may linger for a while after the last shot; no trial has checked. Tell your doctor about anything that lingers or starts after you stop, and read is retatrutide safe for the wider safety picture.